Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity.

Armirotti A, Tomati V, Matthes E, Veit G, Cholon DM, Phuan PW, Braccia C, Guidone D, Gentzsch M, Lukacs GL, Verkman AS, Galietta LJV, Hanrahan JW, Pedemonte N.

Sci Rep. 2019 Jul 16;9(1):10310. doi: 10.1038/s41598-019-46639-1.

2.

Synthesis and evaluation of tetrahydropyrazolopyridine inhibitors of anion exchange protein SLC26A4 (pendrin).

Zhu JS, Lu JY, Tan JA, Rivera AA, Phuan PW, Shatskikh ME, Son JH, Haggie PM, Verkman AS, Kurth MJ.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2119-2123. doi: 10.1016/j.bmcl.2019.07.003. Epub 2019 Jul 3.

PMID:
31281021
3.

SLC26A3 inhibitor identified in small molecule screen blocks colonic fluid absorption and reduces constipation.

Haggie PM, Cil O, Lee S, Tan JA, Rivera AA, Phuan PW, Verkman AS.

JCI Insight. 2018 Jul 26;3(14). pii: 121370. doi: 10.1172/jci.insight.121370. eCollection 2018 Jul 26.

4.

Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.

Phuan PW, Son JH, Tan JA, Li C, Musante I, Zlock L, Nielson DW, Finkbeiner WE, Kurth MJ, Galietta LJ, Haggie PM, Verkman AS.

J Cyst Fibros. 2018 Sep;17(5):595-606. doi: 10.1016/j.jcf.2018.05.010. Epub 2018 Jun 12.

5.

ΔF508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter.

Phuan PW, Veit G, Tan JA, Roldan A, Finkbeiner WE, Haggie PM, Lukacs GL, Verkman AS.

SLAS Discov. 2018 Sep;23(8):823-831. doi: 10.1177/2472555218763310. Epub 2018 Mar 13.

6.

The aquaporin-4 water channel as a potential drug target in neurological disorders.

Verkman AS, Smith AJ, Phuan PW, Tradtrantip L, Anderson MO.

Expert Opin Ther Targets. 2017 Dec;21(12):1161-1170. doi: 10.1080/14728222.2017.1398236. Epub 2017 Nov 5. Review.

7.

Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A).

Truong EC, Phuan PW, Reggi AL, Ferrera L, Galietta LJV, Levy SE, Moises AC, Cil O, Diez-Cecilia E, Lee S, Verkman AS, Anderson MO.

J Med Chem. 2017 Jun 8;60(11):4626-4635. doi: 10.1021/acs.jmedchem.7b00020. Epub 2017 May 24.

8.

High-Potency Phenylquinoxalinone Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators.

Son JH, Zhu JS, Phuan PW, Cil O, Teuthorn AP, Ku CK, Lee S, Verkman AS, Kurth MJ.

J Med Chem. 2017 Mar 23;60(6):2401-2410. doi: 10.1021/acs.jmedchem.6b01759. Epub 2017 Mar 9.

9.

Nanomolar-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prosecretory Therapy of Dry Eye Diseases.

Lee S, Phuan PW, Felix CM, Tan JA, Levin MH, Verkman AS.

J Med Chem. 2017 Feb 9;60(3):1210-1218. doi: 10.1021/acs.jmedchem.6b01792. Epub 2017 Jan 31.

10.

Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.

Haggie PM, Phuan PW, Tan JA, Xu H, Avramescu RG, Perdomo D, Zlock L, Nielson DW, Finkbeiner WE, Lukacs GL, Verkman AS.

J Biol Chem. 2017 Jan 20;292(3):771-785. doi: 10.1074/jbc.M116.764720. Epub 2016 Nov 28.

11.

Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins.

Cil O, Phuan PW, Gillespie AM, Lee S, Tradtrantip L, Yin J, Tse M, Zachos NC, Lin R, Donowitz M, Verkman AS.

FASEB J. 2017 Feb;31(2):751-760. doi: 10.1096/fj.201600891R. Epub 2016 Nov 8.

12.

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

Cil O, Phuan PW, Son JH, Zhu JS, Ku CK, Tabib NA, Teuthorn AP, Ferrera L, Zachos NC, Lin R, Galietta LJV, Donowitz M, Kurth MJ, Verkman AS.

Transl Res. 2017 Apr;182:14-26.e4. doi: 10.1016/j.trsl.2016.10.003. Epub 2016 Oct 15.

13.

Small-Molecule Inhibitors of Pendrin Potentiate the Diuretic Action of Furosemide.

Cil O, Haggie PM, Phuan PW, Tan JA, Verkman AS.

J Am Soc Nephrol. 2016 Dec;27(12):3706-3714. Epub 2016 May 6.

14.

CFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipation.

Cil O, Phuan PW, Lee S, Tan J, Haggie PM, Levin MH, Sun L, Thiagarajah JR, Ma T, Verkman AS.

Cell Mol Gastroenterol Hepatol. 2016 May;2(3):317-327. Epub 2016 Jan 9.

15.

Experimental Evaluation of Proposed Small-Molecule Inhibitors of Water Channel Aquaporin-1.

Esteva-Font C, Jin BJ, Lee S, Phuan PW, Anderson MO, Verkman AS.

Mol Pharmacol. 2016 Jun;89(6):686-93. doi: 10.1124/mol.116.103929. Epub 2016 Mar 18.

16.

Inhibitors of pendrin anion exchange identified in a small molecule screen increase airway surface liquid volume in cystic fibrosis.

Haggie PM, Phuan PW, Tan JA, Zlock L, Finkbeiner WE, Verkman AS.

FASEB J. 2016 Jun;30(6):2187-97. doi: 10.1096/fj.201600223R. Epub 2016 Mar 1.

17.

Small-molecule CFTR activators increase tear secretion and prevent experimental dry eye disease.

Flores AM, Casey SD, Felix CM, Phuan PW, Verkman AS, Levin MH.

FASEB J. 2016 May;30(5):1789-97. doi: 10.1096/fj.201500180. Epub 2016 Feb 3.

18.

Synthesis and evaluation of 5,6-disubstituted thiopyrimidine aryl aminothiazoles as inhibitors of the calcium-activated chloride channel TMEM16A/Ano1.

Piechowicz KA, Truong EC, Javed KM, Chaney RR, Wu JY, Phuan PW, Verkman AS, Anderson MO.

J Enzyme Inhib Med Chem. 2016 Dec;31(6):1362-8. doi: 10.3109/14756366.2015.1135912. Epub 2016 Jan 22.

19.

Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.

Phuan PW, Veit G, Tan JA, Finkbeiner WE, Lukacs GL, Verkman AS.

Mol Pharmacol. 2015 Oct;88(4):791-9. doi: 10.1124/mol.115.099689. Epub 2015 Aug 5.

20.
21.

Structure-activity analysis of thiourea analogs as inhibitors of UT-A and UT-B urea transporters.

Esteva-Font C, Phuan PW, Lee S, Su T, Anderson MO, Verkman AS.

Biochim Biophys Acta. 2015 May;1848(5):1075-80. doi: 10.1016/j.bbamem.2015.01.004. Epub 2015 Jan 19.

22.

ΔF508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles.

Ye L, Hu B, El-Badri F, Hudson BM, Phuan PW, Verkman AS, Tantillo DJ, Kurth MJ.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5840-5844. doi: 10.1016/j.bmcl.2014.09.067. Epub 2014 Oct 2.

23.

Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model.

Tradtrantip L, Asavapanumas N, Phuan PW, Verkman AS.

PLoS One. 2014 Sep 5;9(9):e106824. doi: 10.1371/journal.pone.0106824. eCollection 2014.

24.

Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.

Veit G, Avramescu RG, Perdomo D, Phuan PW, Bagdany M, Apaja PM, Borot F, Szollosi D, Wu YS, Finkbeiner WE, Hegedus T, Verkman AS, Lukacs GL.

Sci Transl Med. 2014 Jul 23;6(246):246ra97. doi: 10.1126/scitranslmed.3008889.

25.

Constrained bithiazoles: small molecule correctors of defective ΔF508-CFTR protein trafficking.

Coffman KC, Nguyen HH, Phuan PW, Hudson BM, Yu GJ, Bagdasarian AL, Montgomery D, Lodewyk MW, Yang B, Yoo CL, Verkman AS, Tantillo DJ, Kurth MJ.

J Med Chem. 2014 Aug 14;57(15):6729-38. doi: 10.1021/jm5007885. Epub 2014 Jul 25.

26.

Diuresis and reduced urinary osmolality in rats produced by small-molecule UT-A-selective urea transport inhibitors.

Esteva-Font C, Cil O, Phuan PW, Su T, Lee S, Anderson MO, Verkman AS.

FASEB J. 2014 Sep;28(9):3878-90. doi: 10.1096/fj.14-253872. Epub 2014 May 19.

27.

Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.

Phuan PW, Veit G, Tan J, Roldan A, Finkbeiner WE, Lukacs GL, Verkman AS.

Mol Pharmacol. 2014 Jul;86(1):42-51. doi: 10.1124/mol.114.092478. Epub 2014 Apr 15.

28.

Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.

Verkman AS, Phuan PW, Asavapanumas N, Tradtrantip L.

Brain Pathol. 2013 Nov;23(6):684-95. doi: 10.1111/bpa.12085. Review.

29.

A small molecule screen identifies selective inhibitors of urea transporter UT-A.

Esteva-Font C, Phuan PW, Anderson MO, Verkman AS.

Chem Biol. 2013 Oct 24;20(10):1235-44. doi: 10.1016/j.chembiol.2013.08.005. Epub 2013 Sep 19.

30.

Small molecule screen yields inhibitors of Pseudomonas homoserine lactone-induced host responses.

Valentine CD, Zhang H, Phuan PW, Nguyen J, Verkman AS, Haggie PM.

Cell Microbiol. 2014 Jan;16(1):1-14. doi: 10.1111/cmi.12176. Epub 2013 Aug 22.

31.

ABSOLUTE CONFIGURATION AND BIOLOGICAL PROPERTIES OF ENANTIOMERS OF CFTR INHIBITOR BPO-27.

Snyder DS, Tradtrantip L, Battula S, Yao C, Phuan PW, Fettinger JC, Kurth MJ, Verkman AS.

ACS Med Chem Lett. 2013 May 9;4(5):456-459.

32.

C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.

Phuan PW, Zhang H, Asavapanumas N, Leviten M, Rosenthal A, Tradtrantip L, Verkman AS.

Acta Neuropathol. 2013 Jun;125(6):829-40. doi: 10.1007/s00401-013-1128-3. Epub 2013 May 16.

33.

1,1-Difluoroethyl-substituted triazolothienopyrimidines as inhibitors of a human urea transport protein (UT-B): new analogs and binding model.

Liu Y, Esteva-Font C, Yao C, Phuan PW, Verkman AS, Anderson MO.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3338-41. doi: 10.1016/j.bmcl.2013.03.089. Epub 2013 Apr 1.

34.

A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4.

Phuan PW, Anderson MO, Tradtrantip L, Zhang H, Tan J, Lam C, Bennett JL, Verkman AS.

J Biol Chem. 2012 Oct 26;287(44):36837-44. doi: 10.1074/jbc.M112.408716. Epub 2012 Sep 18.

35.

Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.

Donald MB, Rodriguez KX, Shay H, Phuan PW, Verkman AS, Kurth MJ.

Bioorg Med Chem. 2012 Sep 1;20(17):5247-53. doi: 10.1016/j.bmc.2012.06.046. Epub 2012 Jul 6.

36.

Pharmacokinetics of quinacrine efflux from mouse brain via the P-glycoprotein efflux transporter.

Ahn M, Ghaemmaghami S, Huang Y, Phuan PW, May BC, Giles K, DeArmond SJ, Prusiner SB.

PLoS One. 2012;7(7):e39112. doi: 10.1371/journal.pone.0039112. Epub 2012 Jul 2.

37.

Nanomolar potency and metabolically stable inhibitors of kidney urea transporter UT-B.

Anderson MO, Zhang J, Liu Y, Yao C, Phuan PW, Verkman AS.

J Med Chem. 2012 Jun 28;55(12):5942-50. doi: 10.1021/jm300491y. Epub 2012 Jun 19.

38.

Triazolothienopyrimidine inhibitors of urea transporter UT-B reduce urine concentration.

Yao C, Anderson MO, Zhang J, Yang B, Phuan PW, Verkman AS.

J Am Soc Nephrol. 2012 Jul;23(7):1210-20. doi: 10.1681/ASN.2011070751. Epub 2012 Apr 5.

39.

Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays.

Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS.

J Biol Chem. 2012 Apr 20;287(17):13829-39. doi: 10.1074/jbc.M112.344325. Epub 2012 Mar 5.

40.

Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica.

Tradtrantip L, Zhang H, Anderson MO, Saadoun S, Phuan PW, Papadopoulos MC, Bennett JL, Verkman AS.

FASEB J. 2012 May;26(5):2197-208. doi: 10.1096/fj.11-201608. Epub 2012 Feb 8.

41.

Fluorinated ΔF508-CFTR correctors and potentiators for PET imaging.

Davison HR, Solano DM, Phuan PW, Verkman AS, Kurth MJ.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1602-5. doi: 10.1016/j.bmcl.2011.12.128. Epub 2012 Jan 3.

42.

Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.

Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, Bennett JL, Verkman AS.

Ann Neurol. 2012 Mar;71(3):314-22. doi: 10.1002/ana.22657. Epub 2012 Jan 23.

43.

Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ΔF508 cystic fibrosis transmembrane conductance regulator protein.

Knapp JM, Wood AB, Phuan PW, Lodewyk MW, Tantillo DJ, Verkman AS, Kurth MJ.

J Med Chem. 2012 Feb 9;55(3):1242-51. doi: 10.1021/jm201372q. Epub 2012 Jan 23.

44.

Functional fluorescently labeled bithiazole ΔF508-CFTR corrector imaged in whole body slices in mice.

Davison HR, Taylor S, Drake C, Phuan PW, Derichs N, Yao C, Jones EF, Sutcliffe J, Verkman AS, Kurth MJ.

Bioconjug Chem. 2011 Dec 21;22(12):2593-9. doi: 10.1021/bc2004457. Epub 2011 Nov 18.

45.

Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.

Phuan PW, Yang B, Knapp JM, Wood AB, Lukacs GL, Kurth MJ, Verkman AS.

Mol Pharmacol. 2011 Oct;80(4):683-93. doi: 10.1124/mol.111.073056. Epub 2011 Jul 5.

46.

TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloride channel conductance in airway and intestinal epithelial cells.

Namkung W, Phuan PW, Verkman AS.

J Biol Chem. 2011 Jan 21;286(3):2365-74. doi: 10.1074/jbc.M110.175109. Epub 2010 Nov 17.

47.

Inhibition of Ca2+-activated Cl- channels by gallotannins as a possible molecular basis for health benefits of red wine and green tea.

Namkung W, Thiagarajah JR, Phuan PW, Verkman AS.

FASEB J. 2010 Nov;24(11):4178-86. doi: 10.1096/fj.10-160648. Epub 2010 Jun 25.

48.

Cell division modulates prion accumulation in cultured cells.

Ghaemmaghami S, Phuan PW, Perkins B, Ullman J, May BC, Cohen FE, Prusiner SB.

Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):17971-6. Epub 2007 Nov 7.

49.
50.

Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds.

Phuan PW, Zorn JA, Safar J, Giles K, Prusiner SB, Cohen FE, May BC.

J Gen Virol. 2007 Apr;88(Pt 4):1392-401.

PMID:
17374787

Supplemental Content

Support Center